Oracle said it would pay $17 per share in cash for Phase Forward, a 30 per cent premium over Thursday’s closing price of $13.08.
Phase Forward is the top maker of programmes for managing clinical trials, ahead of Medidata Solutions Inc and Oracle.
Published 17 April 2010, 16:59 IST